June 6, 2025

Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Exploring 183.86% Upside Potential in the Biotech Sector

Rapport Therapeutics, Inc. (NASDAQ: RAPP), a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, is making waves in the healthcare sector with a focus on innovative solutions for central nervous system..

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: A Biotech Player with 113.86% Potential Upside

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is attracting attention in the biotech sector with its promising pipeline of treatments for neurodegenerative diseases and endocrine conditions. Based in Cambridge, Massachusetts, Amylyx is..

Avanos Medical, Inc. (AVNS) Stock Analysis: Navigating Challenges and Opportunities in the Healthcare Sector

Avanos Medical, Inc. (NYSE: AVNS), a key player in the medical devices industry, is currently navigating a challenging landscape. With a market capitalization of $570.19 million, Avanos is making strategic..

Surmodics, Inc. (SRDX) Stock Analysis: Navigating a 44% Potential Upside Amid Revenue Challenges

Surmodics, Inc. (NASDAQ: SRDX), a prominent player in the healthcare sector specializing in medical devices, stands out in the marketplace with a distinct proposition. Based in Eden Prairie, Minnesota, Surmodics..

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Unlocking a 39.83% Potential Upside

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is capturing investor attention with its significant potential upside of 39.83%. As a specialty pharmaceutical company focusing on pain management treatments, Collegium stands at a..

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating a 24% Potential Upside Amidst Biotechnology Challenges

For investors eyeing the biotechnology sector, Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) presents a compelling, albeit challenging, proposition. With a market capitalization of $423.19 million, Ginkgo operates at the intersection..

Septerna, Inc. (SEPN) Stock Analysis: Exploring a 124.97% Potential Upside in the Biotechnology Sector

Septerna, Inc. (NASDAQ: SEPN), a clinical-stage biotechnology company headquartered in South San Francisco, is making waves in the healthcare sector with its innovative approach to treating complex diseases. With a..

Bioventus Inc. (BVS) Stock Analysis: Exploring a Potential 89% Upside in the Medical Devices Sector

Bioventus Inc. (NASDAQ: BVS), a prominent name in the healthcare sector, specializes in medical devices aimed at pain relief and musculoskeletal therapies. Headquartered in Durham, North Carolina, Bioventus has carved..

Maravai LifeSciences Holdings (MRVI) Stock Analysis: Unveiling a 132.98% Potential Upside Amidst Challenges

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) operates at the intersection of biotechnology and healthcare, providing key products that facilitate the development of drug therapies, vaccines, and diagnostics globally. Headquartered in..

Verve Therapeutics, Inc. (VERV) Stock Analysis: Unveiling a Potential 324.67% Upside in the Biotech Sector

Verve Therapeutics, Inc. (NASDAQ: VERV) has been making waves within the biotechnology industry, offering investors a thrilling opportunity with a potential upside of 324.67%, according to recent analyst ratings. This..

Standard BioTools Inc. (LAB) Stock Analysis: Navigating a 138.96% Potential Upside in the Medical Devices Sector

Standard BioTools Inc. (NASDAQ: LAB) is capturing investor attention with its significant potential upside, pegged at 138.96%. As a key player in the medical devices sector, the company specializes in..

Humacyte, Inc. (HUMA) Stock Analysis: Uncovering a Potential 259.87% Upside in the Biotechnology Arena

Humacyte, Inc. (NASDAQ: HUMA), a pioneering entity in the biotechnology sector, is capturing the attention of investors with its innovative approach to developing bioengineered human tissues. Headquartered in Durham, North..

MeiraGTx Holdings plc (MGTX) Stock Analysis: A High-Stakes Bet with 319.71% Potential Upside

For investors with a penchant for high-risk, high-reward opportunities, MeiraGTx Holdings plc (NASDAQ: MGTX) presents an intriguing case. This clinical-stage gene therapy company, focused on treating serious diseases, offers a..

Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A Biotech Gem with 224% Potential Upside

Oruka Therapeutics, Inc. (NASDAQ: ORKA) is making waves in the biotechnology sector with its promising therapeutic developments and compelling stock potential. As a clinical-stage biopharmaceutical company, Oruka is dedicated to..

KalVista Pharmaceuticals, Inc. (KALV): Investor Outlook on a Potential 91.63% Upside

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is drawing significant attention from investors eager to tap into the potential upside of 91.63% suggested by its current average analyst target price. As a..

Castle Biosciences, Inc. (CSTL) Stock Analysis: Unlocking a 110.86% Potential Upside in the Healthcare Diagnostics Sector

Castle Biosciences, Inc. (NASDAQ: CSTL), a prominent player in the healthcare sector focusing on molecular diagnostics, is capturing significant attention from investors seeking substantial growth opportunities. With a market capitalization..

HealthStream, Inc. (HSTM) Stock Analysis: Exploring 21.91% Potential Upside in the Healthcare SaaS Sector

HealthStream, Inc. (NASDAQ: HSTM) stands as a notable player in the health information services industry, delivering essential Software-as-a-Service (SaaS) solutions to healthcare organizations across the United States. With a current..

Opthea Limited (OPT) Stock Analysis: Navigating the Biotech Waters with a Bold Vision in Eye Disease Treatment

Opthea Limited (ASX: OPT), an Australian biotechnology company, is making waves in the healthcare sector with its pioneering approach to treating eye diseases. As a clinical-stage biopharmaceutical entity, Opthea is..

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Promising 76.48% Upside Potential for Biotech Investors

Enliven Therapeutics, Inc. (ELVN), a burgeoning name in the biotechnology industry, presents a compelling opportunity for investors seeking exposure to the healthcare sector. With a market capitalization of $1.05 billion..

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring a 103% Upside Potential in Biotechnology

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) is making waves in the biotechnology sector, presenting a compelling opportunity for investors seeking exposure to cutting-edge cancer therapies. With a market capitalization of $651.17..

Search

Funds

June 6, 2025

Search

Funds

June 6, 2025

FTSE 100

Funds